THE MODERN BIO← Home

MODERN BIO / CURRENT SAFETY & REGULATORY WATCH

UPDATED SEPTEMBER 16, 2026

Safety alerts,
without the noise.

Exact products. Exact identifiers. Primary sources.

We separate recalls and regulatory facts from evidence, emerging technology and marketing—so you can see what changed and what it actually means.

7 SAFETY ALERTS2 REGULATORY WATCHES

HOW TO USE THIS PAGE

Match the product first.
Then contact the right person.

A recall applies to the product, lot, strength and expiration listed in its notice—not automatically to every product in the same category. If you think you have an affected product, verify its label and contact the dispensing pharmacy, manufacturer or clinician for guidance.

01 / CURRENT SAFETY ALERTS

What changed—and
who needs to check.

FDA PUBLISH DATESEP 13
2026HIGH PRIORITY

FDA-POSTED COMPANY RECALL / COMPOUNDED INJECTABLES

Centric Compounding glutathione, Myer's Cocktail and Tri-Immune Boost

Centric Compounding voluntarily recalled six lots nationwide after the products were compounded with a glutathione active ingredient containing elevated endotoxin. The products reached patients through home delivery and were also delivered to prescribers.

GLUTATHIONE
200 mg/mL, 30 mL vial
MYER'S COCKTAIL
30 mL vial
TRI-IMMUNE BOOST
30 mL vial
REASON
Elevated endotoxin
  • Glutathione: lot 062326:B, BUD 8/7/26; lot 070826:A, BUD 8/22/26; lot 072726:D, BUD 9/25/26.
  • Myer's Cocktail: lot 070226:D, BUD 8/16/26; lot 072126:A, BUD 9/4/26.
  • Tri-Immune Boost: lot 071626:B, BUD 8/30/26.
WHAT TO DO

Match the product, lot and beyond-use date on the vial. If they match, contact Centric Compounding, the dispensing pharmacy and the prescribing clinician promptly for recall instructions and clinical guidance. Seek urgent medical care for severe symptoms.

What FDA posted: The company reported nine cases involving fever, chills, chest pain, nausea or vomiting, headache and/or malaise. The recall notice says elevated endotoxin in injectable products can cause serious inflammatory reactions, low blood pressure, anaphylactic shock and death. The notice does not establish how many recalled vials were administered or the outcome of every report.

Open the FDA-posted recall ↗
FDA PUBLISH DATESEP 15
2026HIGH PRIORITY

FDA-POSTED COMPANY RECALLS / SEXUAL-ENHANCEMENT SUPPLEMENTS

A&P Creations X10 and biQ-FEL

A&P Creations voluntarily recalled identified lots of two liquid supplements after FDA laboratory analysis found undeclared sildenafil and tadalafil. These are prescription-drug ingredients, and undeclared exposure can be especially dangerous for people taking nitrate medicines because blood pressure may fall to unsafe levels.

  • X10: seven 15 mL red sachets in a red-and-gold box, UPC 7708075247094. Lots F090824LN16 (exp. 08/2026), F170325LN19 (exp. 03/2027) and F300326LN28 (exp. 03/2028).
  • biQ-FEL: 500 mL liquid bottle. Lots biQ-f001-06-25 (exp. 05/06/27) and biQ-003-01-26 (exp. 01/01/28; barcode 7709799120663).
WHAT TO DO

Check the exact product, packaging, lot and expiration. If they match, contact the seller, manufacturer and a qualified clinician for recall and health guidance—particularly if you use nitrates or experienced symptoms.

What remains known and unknown: The products were sold through Amazon, Walmart.com and naturefuel.us. The company reported no adverse events associated with either recall as of September 14. That does not establish that exposure is safe, and these recalls do not apply to every sexual-wellness supplement.

Read the PDE5 guide →FDA notice: X10 ↗FDA notice: biQ-FEL ↗
CLASS I RECALL / CATCH-UPSEP 08
2026HIGH PRIORITY

FDA-POSTED COMPANY RECALL / PRESCRIBED SLEEP-APNEA DEVICE

BMC Luna G3 APAP, model LG3600

FDA classified a firmware defect as a Class I recall, its most serious device-recall category. Under a specific combination of high pressure, respiratory rate and peak flow, affected devices can display an error and shut down, interrupting prescribed therapy.

MODEL
LG3600
AFFECTED FIRMWARE
G3-2.00.76
CORRECTED VERSION
G3-2.00.77
UDI
06948538363331 / 06948538365892
WHAT TO DO

Check the model, serial number and firmware using the manufacturer's recall lookup, then contact the prescribing clinician and durable-medical-equipment provider to confirm whether the device is affected and arrange the appropriate replacement pathway. Do not change prescribed sleep-apnea therapy without clinical guidance.

Scope and limits: BMC retrospectively reported 20,160 devices, most of which had already been upgraded at the importer's warehouse; the company later estimated that up to 196 units may still carry the affected firmware. FDA's posting says no complaints or serious adverse-event reports had been received. This alert applies to the specified model, firmware and affected serial numbers—not every Luna or APAP device.

Open the FDA recall ↗
FDA COMMUNICATIONSEP 01
2026HIGH PRIORITY

FDA BOXED WARNING / PRESCRIPTION IV IRON

Injectafer (ferric carboxymaltose injection)

FDA approved a boxed warning—the agency's most prominent safety warning—for ferric carboxymaltose injection, currently marketed as Injectafer, because symptomatic hypophosphatemia continues to be reported despite earlier label warnings.

PRODUCT
Ferric carboxymaltose injection
BRAND
Injectafer
RISK
Symptomatic hypophosphatemia
ACTION
Boxed warning added
WHAT FDA SAYS

Patients should report new or worsening muscle weakness or pain, fatigue, bone or joint pain, or confusion to their healthcare provider. FDA recommends phosphate monitoring for patients at risk of low phosphate and for anyone receiving a repeat course within three months. Treatment decisions belong with the prescribing clinician.

What remains uncertain: This is a labeling change, not a recall, and it does not mean every recipient will develop low phosphate. FDA's review found reports after both single and multiple infusions; serious outcomes included hospitalization, prolonged phosphate replacement, osteomalacia and fractures. FDA also found phosphate testing in fewer than 20% of administration episodes in its Sentinel analysis. Individual risk and symptoms require clinical assessment.

Read the iron-status guide →Open the FDA communication ↗
FDA PUBLISH DATEAUG 31
2026HIGH PRIORITY

FDA-POSTED COMPANY RECALL / WEIGHT-LOSS SUPPLEMENT

Lipofit Extreme 2.0 Fat Burner

Ana Salazar Modela Tu Cuerpo Inc. voluntarily recalled one lot nationwide after FDA laboratory testing found undeclared fluoxetine in the daytime tablets and undeclared 2,4-dinitrophenol, or DNP, in the nighttime tablets. The product was marketed as a dietary supplement and sold directly to U.S. consumers online.

PRODUCT
AM and PM tablets
LOT
25M12F
EXPIRATION
09/2027
REASON
Undeclared fluoxetine and DNP
WHAT THE RECALL SAYS

The company announcement posted by FDA directs people with the affected lot to stop using it, keep it separated from children and others, and contact the company for disposition instructions. Do not sell, give away or transfer the product. Contact a clinician if you have experienced symptoms or problems that may be related to its use.

Why this matters: Fluoxetine is a prescription-drug ingredient. DNP is a toxic substance that is not FDA-approved for any use and is illegally marketed for weight loss. The recall notice describes potentially life-threatening cardiac, neurologic and overheating risks. No known adverse events had been reported to the company when the notice was posted; that does not establish that exposure is safe. This alert applies to the identified product and lot.

Open the FDA notice ↗
FDA PUBLISH DATEAUG 24
2026HIGH PRIORITY

FDA-POSTED COMPANY RECALL / PRESCRIPTION DRUG

Vitruvias Thyroid Tablets USP 30 mg

Vitruvias Therapeutics voluntarily recalled one lot after testing confirmed the potential for the tablets to be superpotent. The FDA notice says excess thyroid hormone can cause hyperthyroid symptoms and may create greater risk for older adults, pregnant patients and infants.

LOT
504950
EXPIRATION
9/30/2026
NDC
69680-166-00
REASON
Potential superpotency
WHAT TO DO

Check the manufacturer, strength, lot and expiration on the bottle. If they match, contact the dispensing pharmacy or prescribing clinician. The recall notice specifically says patients should not discontinue the medicine without contacting their healthcare provider for guidance or a replacement prescription.

What we know: No adverse events known to be related to this recall had been reported to Vitruvias when the notice was posted. That does not change the need to verify affected bottles.

Read the thyroid guide →Open the FDA notice ↗
FDA PUBLISH DATEAUG 20
2026HIGH PRIORITY

FDA-POSTED COMPANY RECALL / COMPOUNDED INJECTABLE

Optimal Balance Pharmacy compounded glutathione injection

Optimal Balance Pharmacy voluntarily recalled one lot of compounded glutathione after pharmacy testing identified elevated bacterial endotoxin. The affected product was distributed to consumers in multiple states, including Florida.

STRENGTH
200 mg/mL
PACKAGE
30 mL multi-dose vial
LOT
LG342009076
EXPIRATION
10/4/2026
WHAT THE RECALL SAYS

The company recall posted by FDA directs affected patients to stop using and quarantine the recalled product, contact Optimal Balance Pharmacy for retrieval, and contact the prescribing clinician if symptoms or problems may be related to its use.

Reported reactions: Fever, chills, severe headache, nausea, vomiting, pain and symptoms consistent with an allergic reaction. The notice also describes potentially serious endotoxin-related risks. This is a specific product-lot recall—not evidence that every glutathione product is contaminated.

FDA investigation update — August 27: FDA said it was aware of at least 30 patients with adverse events after IV glutathione made by different compounding pharmacies using Medisca dietary-supplement-grade glutathione, lot 229536. FDA said dietary-supplement-grade material is not appropriate for injectable drugs and that its investigation remains active. The full number of affected products, pharmacies and patients is not yet known.

Open the recall notice ↗Open the FDA investigation update ↗

02 / REGULATORY WATCH

Meaningful changes—
with the limits intact.

FDA AVAILABILITY UPDATESEP 03
2026

REGULATORY FACT / NOT A RECALL

Estradiol transdermal patches

FDA says access to a usual brand or product may vary as demand rises, but estradiol patches remain available.

FDA said it is working with all six manufacturers after reports that some patients have had difficulty readily accessing their usual estradiol transdermal patch. The agency reported that U.S. supply of FDA-approved patches nearly doubled over the preceding year, while availability can still differ by pharmacy and location.

  • This is an availability update—not a recall and not a statement that every estradiol patch is in nationwide shortage.
  • FDA attributes the access pressure to increased demand and says manufacturers are increasing production and capacity.
  • If a usual patch is unavailable, FDA advises contacting the pharmacist and healthcare provider about appropriate FDA-approved options.
  • Patients should not stop or change medication without guidance from their healthcare provider.

What remains unknown: FDA did not provide brand-by-brand, dose-by-dose or local inventory data, so this notice cannot predict whether a particular pharmacy will have a specific product.

Read the menopause therapy guide →Open the FDA update ↗
FDA AUTHORIZATIONAUG 25
2026

REGULATORY FACT / NOT A CONSUMER WELLNESS PICK

Abbott Libre Duo 10 Day

The first U.S. wearable authorized to continuously monitor both glucose and ketones.

FDA authorized the system for people age 2 and older living with diabetes. It measures glucose and ketones in interstitial fluid every minute during its 10-day wear period and can provide alerts when ketones reach a concerning threshold.

  • It is designed around diabetes safety and earlier recognition of rising ketones that may precede diabetic ketoacidosis.
  • FDA says ketone information should be interpreted alongside glucose readings and symptoms.
  • It is not the same product category or use case as Abbott Lingo or Dexcom Stelo, which appear in our OTC wellness-CGM guide.
  • U.S. consumer pricing and launch availability were not provided in the FDA announcement reviewed for this update.
Compare OTC CGMs →Open the FDA authorization ↗

THE MODERN BIO STANDARD

Regulatory facts are not product endorsements.

This page is educational and does not replace product labeling, recall instructions, diagnosis or individualized medical care. If a product identifier matches—or if you have concerning symptoms—contact the appropriate pharmacy, manufacturer or qualified clinician. Seek urgent care for potentially serious symptoms.